GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

Summary

The STAR CNS trial is a 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or optimal biological dose, determine the recommended phase 2 dose, preliminary anti-tumor activity and efficacy of the recommended phase 2 dose of GB5121.

Timeline

Start

2022-05-24

Primary completion

2023-05-11

Completion

2023-05-11

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

Indications